Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

TAMOXIFEN BREAST CANCER PREVENTION TRIAL RESUMPTION RECOMMENDED

  • News

Executive Summary

TAMOXIFEN BREAST CANCER PREVENTION TRIAL RESUMPTION RECOMMENDED by the BCPT End Results and Safety Monitoring Committee, which met on May 4. At a May 11 hearing before the Senate Cancer Coalition chaired by Sens. Feinstein (D-Calif.) and Mack (R-Fla.), National Cancer Institute Community Oncology and Rehabilitation Branch Chief Leslie Ford, MD, testified that the committee recommendation to resume the study with modifications has been approved by the NCI Division of Cancer Prevention and Control's Board of Scientific Counselors.

Table

View full table

Tags:
Latest Headlines

Wegovy's Medicare Part D Prospects: Four Million Lives And Counting?

ICER Debuts Clinical Trial Diversity Assessment Framework

US FDA Wants Advice About Advisory Committees: Try Having Some?

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

See All
UsernamePublicRestriction

Register

PS024484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By